Inhaled Ciprofloxacin as an Alternative Treatment for Infection with Coxiella burnetii
Antibiotics · 13.03.2026 · 15 (3) · 293
DOI: 10.3390/antibiotics15030293 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 13.03.2026. Verfasst von Rachel E Ireland und 13 weiteren Autor:innen. Beteiligte Einrichtung: Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Defence Threat Reduction Agency (DTRA) & UK Ministry of Defence, Defence Threat Reduction Agency.
Abstract (Originalsprache)
Background/Objectives: Q fever, caused by Coxiella burnetii, is typically treated with doxycycline, but its efficacy is limited in chronic cases and may be poorly tolerated. Systemic ciprofloxacin shows limited activity for acute Q fever. However, inhaled liposomal formulations may provide therapeutic benefit.
Methods
Two inhaled ciprofloxacin formulations (Lipoquin® and Apulmiq®) were evaluated in an A/J mouse model of Q fever and compared with intraperitoneal ciprofloxacin and oral doxycycline. Initially, pharmacokinetic studies were performed to determine an appropriate dosing regimen for the inhaled ciprofloxacin formulations. A separate cohort of mice were then infected with C. burnetii and treated once daily via nebulisation with Lipoquin or Apulmiq, initiated at 24, 48, or 72 h post-challenge. Clinical signs, weight change, splenomegaly, bacterial burden, and lung histopathology were evaluated.
Results
Pharmacokinetic analysis confirmed sustained lung concentrations of inhaled ciprofloxacin, supporting once-daily dosing. Inhaled Lipoquin and Apulmiq significantly reduced clinical signs, weight loss, splenomegaly, and pulmonary bacterial burden compared to untreated controls and doxycycline-treated mice. Histopathology revealed decreased lung inflammation and lesion severity following inhalational dosing. Systemic ciprofloxacin slightly reduced splenic bacterial burden but was less effective in controlling pulmonary infection.
Conclusions
Inhaled liposomal ciprofloxacin demonstrated superior protection and reduced respiratory manifestations of Q fever compared to doxycycline and systemic ciprofloxacin. These findings suggest inhaled formulations may represent a viable alternative for the treatment of Q fever pneumonia. Further studies are needed to evaluate clinical applicability and long-term outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UK.
- UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.
- Aradigm Corporation, Hayward, CA 94545, USA.
- Department of Respiratory Sciences, University of Leicester, Leicester LE1 7RH, UK.
ORCID-Profile: Kevin R Bewley, M Gill Hartley, Stuart J Armstrong, Thomas R Laws, James D Blanchard, Igor Gonda
Förderung
- Defence Threat Reduction Agency (DTRA) & UK Ministry of Defence
- Defence Threat Reduction Agency
Zitieren
APA
Ireland, R. E., Bewley, K. R., Hartley, M. G., Hamblin, K. A., Armstrong, S. J., Nelson, M., Laws, T. R., Norville, I. H., Salguero, F. J., Blanchard, J. D., Dayton, F., Gonda, I., Atkins, H. S., & Harding, S. V. (2026). Inhaled Ciprofloxacin as an Alternative Treatment for Infection with Coxiella burnetii. Antibiotics, 15(3), 293. https://doi.org/10.3390/antibiotics15030293
Vancouver
Ireland RE, Bewley KR, Hartley MG, Hamblin KA, Armstrong SJ, Nelson M, et al. Inhaled Ciprofloxacin as an Alternative Treatment for Infection with Coxiella burnetii. Antibiotics. 2026;15(3):293. doi:10.3390/antibiotics15030293
BibTeX
@article{Ireland2026,
author = {Ireland, Rachel E and Bewley, Kevin R and Hartley, M Gill and Hamblin, Karleigh A and Armstrong, Stuart J and Nelson, Michelle and Laws, Thomas R and Norville, Isobel H and Salguero, Francisco J and Blanchard, James D and Dayton, Francis and Gonda, Igor and Atkins, Helen S and Harding, Sarah V},
title = {Inhaled Ciprofloxacin as an Alternative Treatment for Infection with Coxiella burnetii},
journal = {Antibiotics},
year = {2026},
volume = {15},
number = {3},
pages = {293},
doi = {10.3390/antibiotics15030293}
}
EUVIMED